ID: h-f05d11119f
Hypothesis
Pericyte-targeted senolysis or senomorphic therapy will benefit only an early biomarker-defined subgroup with senescent-but-retained pericytes
Therapeutic benefit from pericyte-directed senescence interventions depends on stage.
EvidencePending (0%)📖 8 cit🗣 1 debates✓ 8 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Therapeutic benefit from pericyte-directed senescence interventions depends on stage. If BBB leak and dysfunction occur while PDGFRB+ pericytes are still present but senescent-like, intervention may be disease-modifying; once dropout dominates, senolysis may be ineffective or harmful. This is best treated as a trial-enrichment and therapeutic-window hypothesis rather than a primary biology claim.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["PDGFRB Activation<br/>PDGF-BB Ligand Binding"]
B["Pericyte Recruitment<br/>Blood-Brain Barrier Maintenance"]
C["PDGFRB Signaling<br/>PI3K/AKT and MAPK Pathways"]
D["Pericyte Coverage<br/>Capillary Integrity"]
E["BBB Integrity Loss<br/>Pericyte Dropout in AD"]
F["Neurovascular Coupling<br/>Functional Hyperemia Impaired"]
G["Amyloid Deposition<br/>Cerebral Amyloid Angiopathy"]
H["Hypoperfusion<br/>Chronic Ischemia"]
I["Cognitive Decline<br/>Vascular contributions to dementia"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> H
E --> G
G --> H
H --> I
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style I fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix8 supports2 contradicts
Supports
Pericyte degeneration is associated with BBB breakdown in human AD, suggesting a stage-dependent window before complete mural-cell loss.
Supports
Senescent brain pericytes directly reduce BBB integrity in vitro, supporting a state in which dysfunctional pericytes remain present and pathogenic.
Supports
Early BBB dysfunction can be measured in living humans, enabling biomarker-based enrichment strategies.
Supports
The crosstalk role of CDKN2A between tumor progression and cuproptosis resistance in colorectal cancer.
Supports
Exploring the impact of PDGFD in osteosarcoma metastasis through single-cell sequencing analysis.
Supports
Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis.
Supports
Pachymic acid promotes ferroptosis and inhibits gastric cancer progression by suppressing the PDGFRB-mediated PI3K/Akt pathway.
Contradicts
sPDGFRB is an injury marker rather than a validated in vivo marker of pericyte senescence, weakening patient-selection specificity.
Contradicts
Currently available senolytics are not pericyte-selective, so removing residual mural support could worsen leak or perfusion.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — PDGFRB
No curated PDB or AlphaFold mapping for PDGFRB yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for PDGFRB, CDKN2A, CDKN1A, BCL2, BCL2L1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.1%
Volatility
Low
0.0053
Events (7d)
3
Price History
▼16.0%💾 Resource Usage
LLM Tokens
17,540
$0.0526
Total Cost
$0.0526
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF APPSWE/PSEN1*E9 or P301S transgenic mice receive pericyte-directed senomorphic therapy targeting PDGFRB-BCL2L1 signaling (e.g., BCL-XL sparing senomorphic or PDGFRB agonist that normalizes BCL2L1 e | Early senomorphic treatment preserves pericyte coverage at ≥70%, prevents BBB leakage increase to ≤20% above baseline, and maintains spatial memory performance | — no observation — | pending | 0.55 |
| IF patients with early-stage Alzheimer's disease (CDR 0.5-1.0) stratified by cerebrospinal fluid or PET evidence of PDGFRB+ pericyte senescence (elevated p16INK4a/CDKN2A co-localized with PDGFRB) rece | CSF/plasma fibrinogen ratio reduced ≥30% and hippocampal atrophy limited to ≤2% in early senescent-but-retained pericyte subgroup receiving senolytic, with no s | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF APPSWE/PSEN1*E9 or P301S transgenic mice receive pericyte-directed senomorphic therapy targeting PDGFRB-BCL2L1 signaling (e.g., BCL-XL sparing senomorphic or PDGFRB agonist that normalizes BCL2L1 expression) at 3 months (pre-senescence) versus 8 months (post-dropout) of age AND pericyte density i
Predicted outcome: Early senomorphic treatment preserves pericyte coverage at ≥70%, prevents BBB leakage increase to ≤20% above baseline, and maintains spatial memory pe
Falsification: Late-intervention cohorts demonstrate equivalent pericyte coverage, BBB integrity, and cognitive function as early-treatment cohorts, indicating senolytic/senomorphic benefit does not depend on the pr
pendingconf 45%
IF patients with early-stage Alzheimer's disease (CDR 0.5-1.0) stratified by cerebrospinal fluid or PET evidence of PDGFRB+ pericyte senescence (elevated p16INK4a/CDKN2A co-localized with PDGFRB) receive a pericyte-targeted BCL-2 family senolytic (e.g., navitoclax or BCL-XL inhibitor) within 12 mont
Predicted outcome: CSF/plasma fibrinogen ratio reduced ≥30% and hippocampal atrophy limited to ≤2% in early senescent-but-retained pericyte subgroup receiving senolytic,
Falsification: Advanced-stage patients or biomarker-negative controls demonstrate equivalent or greater BBB integrity improvement and neuroprotection compared to the early biomarker-positive subgroup, indicating tre
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.